Elanders AB: Report from the Annual General Meeting 2024
The Annual General Meeting, led by Chairman of the Board Dan Frohm, decided to:
- adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet,
- discharge the members of the Board and the Chief Executive Officer from liability for the financial year 2023,
- according to the proposal in the summons, distribute a dividend of SEK 4.15 per share for 2023. The record date for the dividend is proposed to be 23 April 2024 and it is expected that the dividend will be disbursed by Euroclear Sweden AB on 26 April 2024,
- for the financial year 2024 grant, according to the proposal in the summons, the Board a remuneration of a total of SEK 4,512,600 including reimbursement for committee work, to be divided among the members as presented in the summons,
- appoint, according to the proposal in the summons, the following members to the Board until the next Annual General Meeting is held in 2025:
Carl Bennet (re-election)
Ulrika Dellby (re-election)
Eva Elmstedt (re-election)
Dan Frohm (re-election)
Erik Gabrielson (re-election)
Anna Hallberg (re-election)
Anne Lenerius (re-election)
Magnus Nilsson (re-election)
Johan Trouvé (re-election) - appoint, according to the proposal in the summons, Dan Frohm as Chairman of the Board,
- approve the proposal given in the summons to re-elect the accounting firm of Öhrlings PricewaterhouseCoopers as company accountant,
- the nomination committee until the next Annual General Meeting will be formed and perform the duties according to the proposal in the summons, and
- approve the remuneration report presented by the Board regarding senior officers.
In his speech, CEO Magnus Nilsson described the Group’s business and development during 2023 and the first quarter 2024. Considering the very challenging year, characterized by falling demand and a negative organic growth, Elanders had a relatively good result in 2023. The year ended on a positive note due to a strong cash flow, which enabled the acquisition of Kammac. Furthermore, Magnus Nilsson also reported on the investments that have been made and the sustainability work that is being carried out within the Group.
The minutes from the Annual General Meeting will be available on the company website as soon as they have been verified.
Elanders AB (publ)
The Board of Directors
through
Magnus Nilsson, President and CEO, Phone: +46 31 750 07 50
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Genmab Announces Financial Results for the First Quarter of 20242.5.2024 17:01:34 CEST | Press release
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated, evaluating epcoritamab in combination with rituximab and lenalidomide compared to chemoimmunotherapy in previously untreated follicular lymphoma The U.S. FDA accepted for Priority Review the sBLA seeking to convert the accelerated approval of Tivdak® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapyGenmab announced the decision of its arbitra
Sampo has received approval for its Group Partial Internal Model2.5.2024 17:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 2 May 2024 at 6:00 pm Sampo has received approval for itsGroup Partial Internal Model Sampo Group has today received approval for its Group Partial Internal Model (PIM) from the Swedish FSA (Finansinspektionen). The Group PIM recognises the risk profile of Sampo’s P&C operations better than the Standard Formula and as of 31 December 2023 it would have reduced the group-level solvency capital requirement (SCR) by EUR 0.3 billion. Sampo will apply the Group PIM in the second quarter and report its solvency based on this for the first time in its Half-Year Financial Report 2024. The Group remains committed to disciplined capital management and will, with the model in use, provide an update on capital allocation with its half-year 2024 results, in line with the communication provided at the Capital Markets Day on 6 March 2024. SAMPO PLC Investor Relations and Group Communications For further information, please contact: Sami Taipalus Head of Investor Relati
Fenix Outdoor: Fenix Outdoor International AG Press release AGM2.5.2024 17:00:00 CEST | Press release
Fenix Outdoors' Annual General Meeting in Solna on May 2, 2024 has been held The meeting resolved to approve the Annual Report for 2023the dividend 2023 to SEK 15.0 (15.0) per B-share and SEK 1.5 (1.5) per A-shareto grant discharge from liability for members of the Board and the Senior Executivesre-election of the Board; Mats Olsson, Ulf Gustafsson, Sebastian von Wallwitz, Susanne Dalsgaard Nordin and Rolf Schmidre-election of Martin Nordin as Chairman of the Boardre-election of Compensation committee; Ulf Gustafsson and Susanne Dalsgaard Nordinre-election of Dr. Philippe Meyer, lawyer, as Independent Proxy (for general meetings held in Switzerland) and Lars Sandberg, lawyer, as Independent Proxy (for General meetings held in Sweden), until the end of the next Annual General Meetingre-election of Ernst & Young Ltd, in Zurich as auditors, until the end of the next Annual General Meetingthe following compensations: Maximum EUR 1,900,000 as total compensation to the Board for the financ
Fenix Outdoor: Fenix Outdoor International AG Pressmeddelande Årsstämma2.5.2024 17:00:00 CEST | Pressemelding
Fenix Outdoors årsstämma i Solna den 2 maj 2024 har genomförts Stämman beslutade om att godkänna årsredovisningen för 2023utdelning för 2023 till 15 SEK (15) per B-aktie och 1,5 SEK (1,5) per A-aktieansvarsfrihet för styrelseledamöter och ledande befattningshavareomval av styrelse; Mats Olsson, Ulf Gustafsson, Sebastian von Wallwitz, Susanne Dalsgaard Nordin och Rolf Schmidomval av Martin Nordin som styrelsens ordförandeomval av ersättningskommitté; Ulf Gustafsson och Susanne Dalsgaard Nordinomval av Dr. Philippe Meyer, jurist, som oberoende ombud (för bolagsstämmor som hålls i Schweiz) och Lars Sandberg, advokat, som oberoende ombud (för bolagsstämmor som hålls i Sverige), fram till slutet av nästa årsstämmaomval av Ernst & Young Ltd, i Zürich som revisorer, fram till slutet av nästa årsstämmaföljande ersättningar: Maximalt EUR 1 900 000 som total ersättning till styrelsen för räkenskapsåret 2025.Maximalt EUR 3 500 000 som total fast ersättning till ledande befattningshavare för räken
Subsea 7 S.A. 2024 Annual General Meeting2.5.2024 16:35:23 CEST | Press release
Luxembourg – 2 May 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY, the Company) today announced that, at the 2024 annual general meeting of shareholders on 2 May 2024, all resolutions were approved, including the payment of a dividend of NOK 6.00 per common share, to be paid in two equal instalments. The minutes of the annual general meeting which detail the resolutions passed and the result of the votes cast in relation to each resolution are attached and available at subsea7.com. ******************************************************************************* Subsea7 creates sustainable value by delivering the offshore energy transition solutions the world needs. Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62. ******************************************************************************* Contact for investment community enquiries: Katherine Tonks Investor Relations Director Tel +44 20 8210 5568 ir@subsea7.com This information is subject to t